Navigation Links
Keryx Biopharmaceuticals Receives Nasdaq Notification
Date:4/25/2008

our actual results to differ materially are the following: There can be no assurance that the Company will apply for inclusion on the Nasdaq Capital Market, or if so, that the Company's application for inclusion on the Nasdaq Capital Market will be approved,, or that if approved and the listing is transferred, that the Company will continue to meet the Nasdaq Capital Market listing requirements, and/or if the Company's application is denied, that the Company will satisfy Nasdaq's conditions for continued listing on the Nasdaq Global Market, that any potential appeal or hearing for a stay of delisting from the Nasdaq Global Market will be successful, or that the Company's common stock will remain listed on the Nasdaq Global Market; that the Company will complete cost- effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
2. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
3. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Keryx Biopharmaceuticals Announces Additions to Management Team
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... - Teva Announces Sufficient Funds to Complete Acquisition, ... Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) and Barr,Pharmaceuticals, ... and its,syndicate of lending banks, arranged by Bank of ... permit them to remain in place,following Barr,s acquisition by ...
... call today at 4:30 p.m. ET -, SOUTH ... MGRM ) today reported financial results for the,quarter ... of $16.1 million for the third quarter of,2008, 55% ... 2007. This,growth was driven by revenue from Trofile(TM) for ...
... Calif., Oct. 27 Abaxis, Inc.,(Nasdaq: ABAX ), ... reported financial results for the fiscal,quarter ended September 30, ... of $27.7 million, up 10% over last year,s comparable,quarter., ... 17% over last year,s,comparable quarter., -- Record medical ...
Cached Biology Technology:Teva and Barr Provide Update on Acquisition 2Teva and Barr Provide Update on Acquisition 3Teva and Barr Provide Update on Acquisition 4Teva and Barr Provide Update on Acquisition 5Monogram Announces 2008 Third Quarter Financial Results 2Monogram Announces 2008 Third Quarter Financial Results 3Monogram Announces 2008 Third Quarter Financial Results 4Monogram Announces 2008 Third Quarter Financial Results 5Monogram Announces 2008 Third Quarter Financial Results 6Monogram Announces 2008 Third Quarter Financial Results 7Monogram Announces 2008 Third Quarter Financial Results 8Monogram Announces 2008 Third Quarter Financial Results 9Monogram Announces 2008 Third Quarter Financial Results 10Monogram Announces 2008 Third Quarter Financial Results 11Monogram Announces 2008 Third Quarter Financial Results 12Monogram Announces 2008 Third Quarter Financial Results 13Monogram Announces 2008 Third Quarter Financial Results 14Monogram Announces 2008 Third Quarter Financial Results 15Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 2Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 3Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 4Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 5Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 6Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 7Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 8Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 9
(Date:9/17/2014)... has learned a great deal about complex social behavior ... have something to teach too. , With their unusually ... cognition, parrots live in a complex social environment---not merely ... bees or ants, but in a dynamic setting of ... most intelligent mammals: dolphins, whales, primates, and social carnivores, ...
(Date:9/16/2014)... morbidity amongst women in Australia is increased by ... today (17 September) in BJOG: An International ... generally enjoy high standards of living; however, existing ... particular between indigenous and non indigenous Australians. , ... impact of socioeconomic position on severe maternal morbidities ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... increase the likelihood of immune complications following bone marrow ... November 22 advance online issue of Nature Genetics ... the donor,s genome but present in the recipient,s, transplants ... known as graft-versus-host disease, in which immune cells from ...
... and technological frontiers. The National Science Foundation has recently ... diverse efforts of the following investigators under the American ... researchers have been awarded grants for investigation of solar ... enhance the capabilities of NJIT,s Big Bear Solar Observatory ...
... to contribute their abstracts to the World Congress on ... meeting devoted to all aspects of osteoporosis and osteoarthritis ... in Florence, Italy from May 5-8, 2010. Beginning ... The submission deadline is February 4, ...
Cached Biology News:Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
Biology Products: